Latest Breaking News On - Cosette pharmaceuticals - Page 1 : vimarsana.com

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Gynecology Collaboration, R&D, and Licensing Deals Trends

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED)...

The 3 Best Penny Stocks to Buy in February 2024

With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.

Lantheus Announces CEO Succession Plan

Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024 Mary Anne Heino to Retire as Chief Executive Officer and...

Lantheus Holdings (LNTH) Announces CEO Succession, Updates Guidance

Palatin Technologies (PTN) Provides Corporate Update, Highlights Strategic Priorities for 2024

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

Cosette Pharmaceutical Acquires Vyleesi

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder Vyleesi® has experienced 8 Consecutive Quarters of...